| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Sensus Healthcare, Inc.$2.91
+0.02 (+0.69%)
F 17Pipeline Score MedTech · Clinical
Market Cap
52.51 M
EPS
-0.47
P/E Ratio
-
Value Trade
87.82 K
SEC Financials
Q1 2026Dilution Risk
25%Revenue
3.39 M
R&D Expenses
1.59 M
Operating CF
-3.75 M
Total Assets
51.55 M
Total Liabilities
6.00 M
Equity
45.54 M
D/E Ratio
12,345
-12.6 %
Week
-20.65 %
1 Month
-17.36 %
3 Month
-17.78 %
6 Month
-4.2 %
5 Year
-48.05 %
All Time
Cash Data
Cash Position
18.33 M
Monthly Burn
1.25 M
Runway
12.1 mo
Burn Trend
SEC Filing
May 13, 2026
Overview
Volume
6.60 K
52 Week Range
2.82 - 5.92
% held by Insiders
17.63 %
% held by Institutions
27.53 %
Enterprise Value
34.59 M
Total Shares
16.46 M
Short %
1.52 %
Float Shares
13.33 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F17
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 15%
Micro Cap (rank 777 of 913)
Percentile RankSensus Healthcare, Inc. has significant pipeline risk (17/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SRTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
SRTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2026-08-21 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
SRTS▲ +0.7%today
Sensus Healthcare to Report Second Quarter 2026 Financial Results and Hold Business Update Conference Call on August 13, 2026
Sensus Healthcare, a medical device company, will announce its financial results for Q2 2026 on August 13, 2026. The company will hold a conference call at 4:30 PM ET to discuss the results and provide a business update. This event will also include a Q&A session for participants.
Read more →SRTSSensus Healthcare Reports First Quarter 2026 Financial Results and Business Highlights
Sensus Healthcare has reported its financial results for the first quarter of 2026, along with key business highlights. The report includes details on revenue and operational performance, although specific figures and insights are not provided in the article. The company continues to focus on its strategic initiatives for growth.
Read more →SRTSSensus Healthcare to Report First Quarter 2026 Financial Results and Hold Business Update Conference Call on May 7, 2026
Sensus Healthcare, Inc. will report its first quarter 2026 financial results on May 7, 2026. The company will hold a conference call at 4:30 PM ET to discuss these results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Files Lawsuit Against SkinCure Oncology for Breach of Contract
Sensus Healthcare has initiated legal action against SkinCure Oncology for breach of contract. This lawsuit highlights significant disputes between the two companies, which could have financial implications. The ongoing legal battle may also divert attention from Sensus Healthcare's primary operations.
Read more →SRTSSensus Healthcare Introduces Sensus Link, Brings Advanced Operating Capabilities to the SRT-100™ Installed Base
Sensus Healthcare has launched Sensus Link, a cloud-based software solution designed to enhance the operational capabilities of its SRT-100 system. This initiative aims to improve workflow and treatment documentation for users, while also creating a recurring revenue opportunity. The company plans to roll out Sensus Link commercially in 2026, targeting both new and existing customers.
Read more →SRTSSensus Launches Sensus Healthcare Financial Services to Facilitate Customer Acquisition of SRT Technology
Sensus Healthcare has launched a new program, Sensus Healthcare Financial Services, aimed at simplifying the acquisition of its superficial radiotherapy systems for dermatology practices. This initiative offers flexible financing options and is designed to enhance financial visibility and reimbursement certainty. The program is expected to streamline the purchasing process, making it more accessible for healthcare providers.
Read more →SRTSSensus Healthcare Reports Fourth Quarter 2025 Financial Results Highlighted by Publication of Dedicated CPT Codes for SRT to Treat Non-Melanoma Skin Cancer 2026 CMS Physician Fee Schedule Final Rule provides a 300% per-f
Sensus Healthcare reported its fourth quarter financial results for 2025, highlighting the publication of dedicated CPT codes for SRT treatments, which significantly boost reimbursement rates. Despite shipping 14 systems in Q4, the company faced a revenue decline from $13.1 million in Q4 2024 to $4.9 million due to reduced sales to its largest customer. Notably, the company experienced an increase in patient treatments, with utilization rising over eight-fold compared to 2024. With a strong balance sheet and expectations of improved shipment performance in early 2026, Sensus aims for full-year profitability.
Read more →SRTSSensus Healthcare to Report Fourth Quarter and Full Year 2025 Financial Results and Hold Business Update Conference Call on February 12, 2026
Sensus Healthcare, Inc. will report its fourth quarter and full year 2025 financial results on February 12, 2026. A conference call will follow at 4:30 p.m. Eastern time, where management will discuss the results and provide a business update. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Appoints Larry Biscotti to its Board of Directors BOCA RATON, Fla. - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive a
Sensus Healthcare, Inc. has appointed Larry Biscotti to its Board of Directors, enhancing its leadership team with his over 25 years of experience in medical devices and healthcare technology. Biscotti, who currently oversees imaging for GE Healthcare in the U.S. and Canada, is expected to contribute significantly to Sensus' strategic direction and commitment to innovative treatment solutions. His previous experience includes leadership roles at several renowned medical technology firms. This appointment reflects Sensus Healthcare's dedication to improving patient outcomes through advanced, patient-centric treatments.
Read more →SRTS▲ +9.3%on this news
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors Seasoned financial executive brings leadership acumen, strategic growth expertise and a strong track record of operational excellence BOCA RATON, Fla. (
Sensus Healthcare has appointed Eric Sachetta to its Board of Directors, succeeding the late Bill McCall. Sachetta, known for his extensive experience in financial services and organizational leadership, is expected to contribute significantly to the company's growth and strategic direction. He has previously led various initiatives in financial planning and has a strong track record in mentoring. Sensus Healthcare continues to innovate in non-invasive treatments for skin cancer and keloids, aiming for superior clinical outcomes.
Read more →SRTSSensus Healthcare Reports Third Quarter 2025 Financial Results Centers for Medicare & Medicaid Services (CMS) established coding validating superficial radiotherapy (SRT) for treating non-melanoma skin cancer Revenues of
Sensus Healthcare reported its financial results for the third quarter of 2025, marking revenues of $6.9 million, a decline from $8.8 million in Q3 2024. A significant development was the introduction of dedicated CPT codes by CMS for superficial radiotherapy (SRT) aimed at treating non-melanoma skin cancer, which is expected to enhance reimbursement processes. Despite positive advancements in product adoption and international interest, the company faced challenges with decreased sales volumes and lower gross margins compared to the previous year.
Read more →SRTSSENSUS INVESTIGATION REMINDER: Bragar Eagel & Squire, Reminds Sensus Healthcare Investors to Contact the Firm Regarding Ongoing Investigation on Behalf of Sensus Stockholders
Bragar Eagel & Squire, P.C. is currently investigating Sensus Healthcare, Inc. (SRTS) on behalf of its stockholders regarding potential violations of federal securities laws. This follows Sensus's recent financial report for Q2 2025, which showed a significant earnings miss and a sharp decline in revenue. As a result of these findings, the company's stock price plummeted by over 35%. The law firm is encouraging affected investors to reach out for information on their legal options.
Read more →SRTSSENSUS ALERT: Bragar Eagel & Squire, P.C. is Investigating Sensus Healthcare, Inc. on Behalf of Sensus Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is investigating Sensus Healthcare, Inc. on behalf of its stockholders due to concerns regarding possible violations of federal securities laws. The investigation follows Sensus's disappointing financial results for the second quarter of 2025, where earnings fell short of estimates, and revenues declined by over 20% year-over-year. Following this news, Sensus's stock price saw a sharp decline of over 35%. The law firm is encouraging affected investors to reach out for more information on their legal rights and options.
Read more →SRTSSensus Healthcare, Inc. Investors: Company Investigated by the Portnoy Law Firm
The Portnoy Law Firm has initiated an investigation into possible securities fraud related to Sensus Healthcare, Inc. (SRTS) and may file a class action lawsuit on behalf of investors. This comes after Sensus reported disappointing financial results for Q2 2025, including a significant loss per share and a sharp decline in revenue. Following the announcement, Sensus's stock price fell by over 35%, prompting concerns among investors regarding potential losses.
Read more →SRTSSensus Healthcare Reports Second Quarter 2025 Financial Results Shipped 19 SRT systems during the quarter, including four to China Revenues of $7.3 million FDA treatment volume increased 27% over the first quarter Exited
Sensus Healthcare, Inc. has reported its financial results for the second quarter of 2025, indicating revenues of $7.3 million, down from $9.2 million in the same quarter last year. The company shipped 19 SRT systems and saw a 27% increase in FDA treatment volume over the previous quarter. However, gross margins have decreased significantly, and a proposed reimbursement policy could impact future sales. Despite these challenges, management believes that the company's strategic initiatives are gaining traction.
Read more →SRTSSensus Healthcare Reports First Quarter 2025 Financial Results 21 SRT systems shipped during the quarter; revenues of $8.3 million 65% increase in treatment volume from FDAs over preceding quarter Profitability forecast
Sensus Healthcare, Inc. (SRTS) announced its financial results for Q1 2025, reporting revenues of $8.3 million, down from $10.7 million in the same period last year. Despite this decrease, the company demonstrated a 65% increase in treatment volume and expressed confidence in its profitability for the upcoming quarters. Sensus's investments in marketing and research are expected to enhance growth, alongside participation in several dermatology conferences. However, the company faced a net loss of $2.6 million, contrasting with last year's profit of $2.3 million.
Read more →SRTSSensus Healthcare Buys Back Shares BOCA RATON, Fla. (
Sensus Healthcare, Inc. has announced the resumption of its share repurchase program, authorized by its Board of Directors, allowing the purchase of up to $3 million of its common stock. The company's CEO, Joe Sardano, highlighted this move as an opportunity to return capital to shareholders while investing in growth initiatives. Previous share repurchase activity under this program occurred in 2022, with over 9,427 shares already bought back. The program's specifics regarding timing and execution will be determined by management based on market conditions and company needs.
Read more →SRTS▲ +6.5%on this news· ran to -28% by day 3
Sensus Healthcare Reports Fourth Quarter and Full Year 2024 Financial Results Shipped a record 39 SRT systems during the quarter; revenues of $13.1 million Achieved fifth consecutive quarter of profitability; diluted EPS
Sensus Healthcare, Inc. reported strong financial results for the fourth quarter and full year 2024, with revenues reaching $13.1 million and a fifth consecutive quarter of profitability. The company shipped a record 39 SRT systems in the fourth quarter, demonstrating increased adoption of their technology. However, Sensus anticipates that sales in the first quarter of 2025 may decline compared to the previous year due to seasonal softening and potential impacts from marketing events. Overall, the company remains focused on expanding its market presence and product offerings.
Read more →SRTSPompano Veterinary Oncology Partners with Sensus Healthcare to Provide First Superficial Radiotherapy Services in a Mobile Configuration
Sensus Healthcare has partnered with Pompano Veterinary Oncology to introduce mobile superficial radiotherapy (SRT) for treating companion animals in South Florida. This innovative service aims to provide high-quality cancer treatment while minimizing stress for pets by offering home visits and clinic services. The SRT-100 system will enhance the clinic's existing oncology offerings.
Read more →SRTS▲ +10.1%on this news
REVISED - Sensus Healthcare Reports Third Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Third Quarter
Sensus Healthcare reported a significant increase in revenues for Q3 2024, with a 127% rise compared to Q3 2023. The company achieved profitability and signed multiple agreements under its new revenue-sharing model. Management anticipates continued growth driven by the demand for SRT treatments for skin cancer. The company also highlighted the potential of its proprietary software in enhancing operational efficiency.
Read more →SRTS▲ +6%on this news· ran to +22% by day 3shared move
Sensus Healthcare Reports Third Quarter 2024 Financial Res ults With Revenues More than Doubling Versus 2023 Third Quarter Revenues of $8.8 million compare with $3.9 million in the prior-year quarter, adjusted EBITDA (a
Sensus Healthcare, Inc. reported significant financial growth in the third quarter of 2024, with revenues reaching $8.8 million, more than doubling from $3.9 million in the same quarter of 2023. The company attributes this increase to successful engagement with both new and existing customers, along with the introduction of their Fair Deal Agreement aimed at facilitating customer investments. Notably, the company signed agreements with a growing network of dermatology clinics, positioning itself well in a significant market for non-melanoma skin cancer treatments. Despite increased sales costs and administrative expenses, Sensus maintained profitability, marking a successful quarter in its overall performance.
Read more →SRTS▲ +6%on this news· ran to +22% by day 3shared move
This revised news release replaces the one issued on
Sensus Healthcare (SRTS) reported substantial financial growth in its third quarter of 2024, with revenues rising by 127% to $8.8 million. The company's profitability reflects its successful customer engagement strategies, including a popular revenue-sharing agreement. Notably, the firm surpassed its goal of signing up to 50 Fair Deal Agreements by the end of 2024. Furthermore, Sensus expects to generate recurring revenue from SRT-100 Vision systems in 2025 while addressing the growing demand for non-melanoma skin cancer treatments.
Read more →SRTS▼ -5.2%on this news
Sensus Healthcare to Host Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 14, 2024
Sensus Healthcare, Inc. will hold a conference call on November 14, 2024, to discuss its third quarter financial results and provide a business update. The call will include discussions on recent milestones and future plans. Participants can pre-register for the call or join via dial-in options.
Read more →SRTSSensus Healthcare Sells SRT System to Providence Swedish Hospital
Sensus Healthcare has shipped an SRT system to Providence Swedish Hospital, enhancing their oncology capabilities. The system is noted for its effectiveness in treating skin cancers and is part of a growing trend towards non-invasive treatments. The CEO expressed optimism about increasing inquiries from hospitals nationwide for such technologies.
Read more →SRTS▲ +6.4%on this news
Sensus Healthcare Reports Second Quarter 2024 Financial Results With Revenues More than Doubling Versus 2023 Second Quarter Revenues of $9.2 million compare with $4.5 million in the prior-year quarter, a djusted EBITDA (
Sensus Healthcare reported notable financial results for the second quarter of 2024, achieving revenues of $9.2 million, more than doubling from the prior year's $4.5 million. The company recorded a positive net income of $1.6 million, a considerable improvement from a net loss in the same quarter of 2023. Sales momentum has been strong, particularly driven by an agreement with 15 customers for SRT-100 Vision systems. Furthermore, Sensus Healthcare is expanding its presence in Asia, aiming to make SRT treatments the standard care for certain skin cancers.
Read more →SRTSSensus Healthcare Issues Reminder That its Second Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, August 8, 2024
Sensus Healthcare, Inc. will hold a conference call on August 8, 2024, to discuss its second quarter financial results and provide a business update. The call will include discussions on recent and upcoming milestones. Participants can pre-register for the call or access it via phone. A replay will be available after the call.
Read more →SRTSSensus Healthcare to Host Second Quarter 2024 Financial Results and Business Update Conference Call on Thursday, August 8, 2024
Sensus Healthcare, Inc. will hold a conference call on August 8, 2024, to discuss its financial results for the second quarter of 2024. During this call, management will also provide a business update and discuss recent and upcoming milestones. The call will be accessible via pre-registration and will be webcast live. Following the call, a replay will be available for a limited time.
Read more →SRTSLargest Veterinary Emergency Hospital in Tel Aviv Acquires Sensus Healthcare’s SRT-100™ to Provide Gentler Radiotherapy to Treat Tumors in Dogs and Cats
Sensus Healthcare has announced the first commercial sale of its SRT-100 system for veterinary use outside the U.S. to Chavat Da’at in Tel Aviv. This system will provide a gentler radiotherapy option for treating tumors in dogs and cats. The sale signifies a growth opportunity for Sensus in the veterinary sector, expanding access to advanced treatment options for pet owners.
Read more →SRTSSensus Healthcare Reports First Quarter 2024 Financial Results With Revenues up More than Three-fold Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; A djusted EBITDA (a non-GAAP measure)
Sensus Healthcare reported strong financial results for Q1 2024, with revenues increasing to $10.7 million from $3.4 million in the previous year. The company also posted a net income of $2.3 million, a significant turnaround from a net loss in Q1 2023. Key developments included the sale of the first SRT-100 Vision System in Asia and a veterinary sale in Israel, reinforcing market expansion. The introduction of the Fair Deal Agreement program is expected to enhance customer engagement and revenue growth.
Read more →SRTSSensus Healthcare Announces Sale of First SRT-100 Vision™ System to Asia
Sensus Healthcare has announced the sale of its first SRT-100 Vision system to Far Eastern Memorial Hospital in Taiwan, a significant milestone for the company in the Asian market. The hospital plans to research new indications for the system, which could lead to expanded uses beyond non-melanoma skin cancer. This sale is expected to pave the way for further sales in the region, including China.
Read more →SRTSSensus Healthcare Issues Reminder That its First Quarter 2024 Financial Results and Business Update Conference Call Will be Held on Thursday, May 9, 2024
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced a conference call scheduled for May 9, 2024, at 4:30 p.m. Eastern time to discuss its first quarter financial results and provide a business update. This event is designed to keep investors informed about the company's recent and upcoming milestones. The call can be accessed via pre-registration or by dialing in directly, and it will also be web-streamed live. A replay of the call will be available for a limited time following the event.
Read more →SRTSSensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
Sensus Healthcare, a medical device company focused on non-invasive treatments, announced it will hold a conference call on May 9, 2024, to discuss its first quarter 2024 financial results. The call will also include updates on the company's business and milestones. Participants can register in advance to bypass live operators, and the call will be webcasted for broader accessibility. An archived version will be available post-call.
Read more →SRTSSensus Healthcare to Participate in the 36th Annual Roth Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced its participation in the 36th Annual Roth Conference, scheduled from March 17th to 19th in Dana Point, California. During one-on-one meetings, the management will present its Fair Deal Agreement for the SRT-100 Vision™ IG-SRT, which aims to enhance customer value and create a recurring revenue model. The company will also share insights from its recent participation at the American Academy of Dermatology Annual Meeting. Attendance at the conference is by invitation only for institutional investors.
Read more →SRTS▲ +9.6%on this newsshared move
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
Sensus Healthcare has successfully launched its 'Fair Deal Agreement' for the SRT-100 Vision at the American Academy of Dermatology Annual Meeting. This initiative aims to enhance access to their unique superficial radiotherapy technology for dermatology practices. The company reported an unprecedented level of sales leads at the event, highlighting significant market interest. The Fair Deal Agreement is designed to provide a cost-effective alternative for treating non-melanoma skin cancer, complementing Sensus's existing sales strategies.
Read more →SRTSSensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results Fourth quarter revenues of $12.6 million up three-fold sequentially, reflect ongoing customer adjustment to macroeconomic conditions Introduce
Sensus Healthcare, Inc. released its financial results for Q4 and full year 2023, reporting a revenue of $12.6 million in Q4, a three-fold increase from the previous quarter. Despite this, the company experienced a significant decrease in full-year revenue and net income compared to 2022, influenced by customer purchasing deferrals linked to macroeconomic conditions. The company initiated a collaboration with CureRays to extend treatment applications and is focusing on expanding international sales in the coming years, despite challenges faced in their domestic market.
Read more →SRTSSensus Healthcare Issued U.S. Patent for SRT-100 Vision System (IG-SRT) Capabilities
Sensus Healthcare, Inc. announced that the U.S. Patent and Trademark Office granted it Patent No. 11,894,123 B2 for its SRT-100 Vision system. This patent covers a treatment-planning system that integrates a radiation therapy device with high-frequency ultrasound. The technology aims to improve patient treatment outcomes by enabling clinicians to create precise treatment plans. Additionally, this patent fortifies Sensus' intellectual property, securing its innovations for the future.
Read more →SRTS▲ +7.7%on this news· ran to +20% by day 3shared move
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
Sensus Healthcare, Inc. has entered a significant collaboration with CureRays to enhance patient safety and compliance for dermatology customers using superficial radiotherapy (SRT). This partnership aims to research new therapeutic indications for SRT, including applications for inflammatory diseases like arthritis. The collaboration reflects a commitment to improving patient care through innovations in radiation oncology and addresses the evolving regulatory landscape surrounding radiation usage. The involvement of experts from CureRays is expected to support the broader adoption of Sensus's technologies in various clinical settings.
Read more →SRTSSensus Healthcare Announces Retirement of Director Samuel O’Rear
Sensus Healthcare, Inc. (SRTS) has announced that Samuel O'Rear will retire and not seek reelection to the Board of Directors during the upcoming 2024 annual meeting. O'Rear has been a director since 2012, and the company expressed appreciation for his significant contributions. In a related development, Michael J. Sardano has been appointed as a new director, with hopes for continued success and valuable input in the future. The company remains focused on providing innovative, non-invasive treatments in the healthcare industry.
Read more →SRTSSensus Healthcare to Host Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call on Thursday, February 8, 2024
Sensus Healthcare, Inc. will host a conference call on February 8, 2024, to discuss its fourth quarter and full year 2023 financial results. The call will also include a business update and an overview of recent and forthcoming milestones. Interested participants can pre-register for the call or join via a dedicated dial-in number. A web broadcast of the call will be available, along with a replay option after the event.
Read more →SRTS▲ +26.3%on this news
Sensus Healthcare Announces Preliminary 2023 Revenue Exceeds $23 Million
Sensus Healthcare, Inc. (SRTS) announced preliminary unaudited financial results indicating full-year revenue surpassing $23 million for 2023. The company reported over $12 million in revenue for the fourth quarter and successfully shipped more than 60 SRT systems during the year. CEO Joe Sardano expressed optimism regarding increasing utilization of their treatments for skin cancer and highlighted expected strong interest at upcoming industry conferences. Full details on financial performance will be released on February 8, 2024.
Read more →SRTSSensus Healthcare Reports Third Quarter 2023 Financial Results Revenues of $3.9 million reflect seasonality and macroeconomic conditions Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare, Inc. reported third quarter financial results for 2023, showing revenues of $3.9 million, significantly down from $9.0 million a year prior. The decrease is attributed primarily to a lower number of SRT units sold and declining sales to a major customer. Despite these challenges, the company is focusing on expanding its market presence, particularly in the Northeast U.S. and international markets, while also enhancing its offerings with new software features. The company remains optimistic about its revenue potential in the upcoming fourth quarter as it leverages its inventory and cash position.
Read more →SRTSSensus Healthcare to Host Third Quarter 2023 Financial Results and Business Update Conference Call on Thursday, November 9, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS) announced a conference call scheduled for November 9, 2023, at 4:30 p.m. ET to discuss its third quarter financial results. The management will also share a business update along with recent and upcoming milestones. This upcoming event demonstrates the company's commitment to keeping stakeholders informed about its performance and strategic direction.
Read more →SRTSSensus Healthcare to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology Conference
Sensus Healthcare, Inc. (Nasdaq: SRTS) will participate in the Roth MKM 2023 Healthcare Opportunities Conference on October 12 in New York City, as well as the 43rd Annual Fall Clinical Dermatology Conference from October 19-22 in Las Vegas. The company plans to present advancements in its superficial radiotherapy technology, including live demonstrations of its devices. CEO Joe Sardano will deliver a presentation at the Yale Club, emphasizing the company's innovations in treating oncological and non-oncological conditions.
Read more →SRTSSensus Healthcare Sells Superficial Radiotherapy System to Cape Cod Hospital
Sensus Healthcare, Inc. has announced the successful shipment of its SRT-100+ System to Cape Cod Hospital, marking the second installation in Massachusetts. This sale demonstrates the increasing interest in Sensus' non-invasive skin cancer treatment technology. With a focus on outpatient care, the SRT systems are positioned as effective alternatives for patients who might not want or be able to opt for surgical procedures. The company will showcase their products at the upcoming ASTRO Annual Meeting in San Diego, further emphasizing their commitment to innovation in radiation oncology.
Read more →SRTSSensus Healthcare to Showcase its Full Line of Cutting-Edge Superficial Radiotherapy Devices for the Treatment of Non-melanoma Skin Cancer at ASTRO 2023 in San Diego
Sensus Healthcare, Inc. (Nasdaq: SRTS) will participate in the ASTRO 2023 Annual Meeting in San Diego from October 1-4, where it will showcase its advanced superficial radiotherapy devices for treating non-melanoma skin cancer. The company aims to provide healthcare professionals insights into their innovative, non-invasive treatment options. With devices like the SRT-100 and its IT Solutions product, Sensus Healthcare focuses on patient-centric solutions that integrate seamlessly into healthcare systems. The meeting offers a platform for Sensus to engage with radiation oncologists and demonstrate the effectiveness of their products.
Read more →SRTS▲ +13.3%on this news
Sensus Healthcare Announces New $3 Million Share Repurchase Program
Sensus Healthcare has announced a new share repurchase program authorized by its Board of Directors, allowing for the buyback of up to $3 million of its common stock. CEO Joe Sardano expressed optimism about the company's future and asserted that repurchasing stock is a beneficial use of capital. The timing and execution of the repurchases will depend on market conditions and the company's financial assessments. Despite the positive sentiment around the repurchase, there are uncertainties related to market fluctuations and external economic risks that may impact future performance.
Read more →SRTS▼ -5.6%on this news· ran to +36% by day 3shared move
Sensus Healthcare Reports Second Quarter 2023 Financial Results Revenues increased 33% and system shipments increased 30%, both compared with the first quarter of 2023 Achieved a milestone with the installation of 700 sy
Sensus Healthcare, Inc. reported a positive financial trajectory for the second quarter of 2023, with a 33% increase in revenues and a 30% rise in system shipments compared to the previous quarter. The company emphasized its goal to return to profitability in the latter half of the year, supported by improved patient volumes and partnerships, including one with MIS Healthcare for distribution in the UK. Despite achieving significant milestones, such as surpassing 700 system installations, Sensus reported a net loss of $0.4 million, reflecting a decline from prior year earnings.
Read more →SRTSSensus Healthcare to Host Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 3, 2023
Sensus Healthcare, Inc. will host a conference call on August 3, 2023, at 4:30 p.m. ET to discuss its second-quarter financial results for 2023. During the call, management will also provide a business update and discuss recent and upcoming milestones. The call will be accessible via pre-registration, and a replay will be available post-event until September 3rd.
Read more →SRTSSensus Healthcare Completes Installation of its First SRT System in Ireland
Sensus Healthcare has successfully installed its first SRT-100 system in Ireland at Dublin's Beacon Hospital, marking a significant expansion of radiotherapy services for non-melanoma skin cancer patients. The SRT-100 will provide a non-invasive treatment solution for up to 12,000 patients affected by non-melanoma skin cancers annually in Ireland. Dr. Siobhra O'Sullivan expressed enthusiasm for the new unit, while Sensus CEO Joe Sardano acknowledged this sale as a potential stepping stone for future installations in Ireland and the UK.
Read more →SRTSSensus Healthcare Partners with MIS Healthcare to Distribute SRT Systems in the United Kingdom and Ireland
Sensus Healthcare, Inc. has announced a partnership with MIS Healthcare to distribute its superficial radiation therapy (SRT) systems in the United Kingdom and Ireland. This includes products such as the SRT-100™, SRT-100+™, and SRT-100 Vision™, aimed at treating non-melanoma skin cancer and keloids. The agreement is expected to enhance visibility and market access for Sensus's innovative, non-invasive treatment solutions. With nearly 600 daily diagnoses of skin cancer in these regions, this collaboration aims to provide patients a new, effective treatment option.
Read more →SRTSSensus Healthcare to Participate in the Maxim Group Virtual Healthcare Conference Hosted by M-Vest
Sensus Healthcare, Inc. (Nasdaq: SRTS) will participate in the Maxim Group Virtual Healthcare Conference hosted by M-Vest on June 20, 2023. Key executives, including Joe Sardano and Javier Rampolla, will be featured on a panel focused on the aesthetics industry. The conference provides an opportunity for Sensus to discuss its innovative medical device treatments, including its proprietary superficial radiation therapy technology. The event is expected to enhance the company's visibility and engage with potential investors.
Read more →SRTSSensus Healthcare's SRT Treatment Shows Promise in Treating Cutaneous Mast Cell Tumors Among Pet Patients
Sensus Healthcare has reported promising results from its SRT-100 system in treating cutaneous mast cell tumors (MCTs) in pets, based on a limited study published in a veterinary journal. The retrospective case series indicated a complete response in all cases that followed the treatment protocol, with no significant adverse side effects observed. Dr. Tiffany W. Martin expressed optimism about SRT-100 serving as an effective alternative to traditional MCT treatments, such as surgery or chemotherapy. The company plans to bring this non-invasive and cost-effective treatment for pets to market.
Read more →SRTS▲ +7.5%on this news· ran to -40% by day 1
Sensus Healthcare Reports First Quarter 2023 Financial Results Lower demand for SRT systems reflects the impact of inflation on dermatologists' cash flow from fewer elective aesthetic procedures and higher operating cost
Sensus Healthcare reported disappointing financial results for the first quarter of 2023, citing lower demand for SRT systems due to inflation impacting dermatologists' business. Revenue fell significantly compared to the previous year, leading to a net loss. Despite these challenges, the company aims to ship over 60 SRT units and anticipates a return to profitability in the latter half of the year. Sensus is also focusing on market expansion into new international territories and investments in software solutions.
Read more →SRTSSensus Healthcare to Host First Quarter 2023 Financial Results and Business Update Conference Call on Wednesday, May 3, 2023
Sensus Healthcare, Inc. (SRTS) will conduct a conference call on May 3, 2023, to review its financial results for the first quarter of 2023. The call will also include a business update and discussions on recent developments and upcoming milestones. The company specializes in non-invasive treatments for oncological and non-oncological conditions. Participants can pre-register to avoid the live operator and access a replay after the call's conclusion.
Read more →SRTSSensus Healthcare announces the Sensus Cloud™; Unveils New Features at American Academy of Dermatology (AAD) Annual Meeting in New Orleans March 17-19
Sensus Healthcare announced the launch of Sensus Cloud during the American Academy of Dermatology Annual Meeting. This innovative cloud-based platform aims to improve patient care by integrating asset management and electronic medical records. Notable features include real-time monitoring, AI-assisted data access for healthcare providers, and predictive analytics for treatment planning. The company emphasizes the platform's security measures to protect sensitive patient information.
Read more →SRTSSensus Healthcare Fourth Quarter 2022 Financial Results Include Quarterly Revenues of $13.1 Million Full-year revenues increased 65% to $44.5 million Investments in technology and staff position Sensus for growth in 2023
Sensus Healthcare reported fourth quarter 2022 revenues of $13.1 million and full-year revenues of $44.5 million, marking a significant 65% increase year-over-year. The company is making strategic investments in technology and staff to drive growth, including new product developments and enhancements to existing systems. Despite a decrease in quarterly net income and gross profit margin due to rising manufacturing costs, Sensus plans for continued expansion in the coming year. The financial performance reflects the company's successful execution of its business strategy amid increasing demand for its products.
Read more →SRTSSensus Healthcare to Host Fourth Quarter 2022 Financial Results and Business Update Conference Call on February 9, 2023
Sensus Healthcare, Inc. (Nasdaq: SRTS) has announced that it will hold a conference call on February 9, 2023, at 4:30 PM ET to discuss its fourth quarter and full year 2022 financial results. During this call, management will provide a business update and outline recent and upcoming milestones. The conference call can be accessed via dial-in or a live webcast. A replay of the call will be available until March 9, 2023.
Read more →SRTS▲ +7.1%on this news
Sensus Healthcare Announces Senior Management Appointments and Promotions
Sensus Healthcare, Inc. has announced several key promotions and appointments within its senior management team. Maggie Martinez has been promoted to Chief Operating Officer, while Emiliano Sosa takes on the role of Chief Technical Officer. Stephanie Tipton has been elevated to Vice President of Marketing, with Sean Delaney as Vice President of Regulatory and Quality Assurance, and Wayne Lura as Vice President of Aesthetic Sales. The company's leadership believes these changes will bolster growth and innovation as they implement an aggressive business strategy.
Read more →SRTSSensus Healthcare Announces Preliminary Fourth Quarter 2022 Revenues Fourth quarter revenues to exceed $13 million; full year revenues to exceed $44 million, representing growth of 60%
Sensus Healthcare has announced preliminary financial results for the fourth quarter of 2022, with revenues expected to exceed $13 million and full year revenues anticipated to surpass $44 million. This signifies a notable growth of approximately 60% compared to 2021. The company plans to expand its domestic sales force and increase its presence at trade shows throughout 2023, as well as enhance its product portfolio with several FDA submissions expected later in the year. A full financial report and an investment community conference call are scheduled for February 9, 2023.
Read more →SRTSSensus Healthcare Reports Third Quarter 2022 Financial Results Profitability continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago Conference call begins at 4:30 p.m. Eastern
Healthcare Reports Third Quarter 2022 Financial Results continues with revenues up 64% to $9.0 million, diluted EPS of $0.11 compares with $0.01 a year ago call begins at 4:30 p.m. Eastern time today RATON, Fla. (November 3, 2022) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a me
Read more →SRTSSensus Healthcare to Host Third Quarter 2022 Financial Results and Business Update Conference Call on November 3, 2022
BOCA RATON, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference cal
Read more →SRTSSensus Healthcare Introduces Silk™ Laser Hair Removal System
BOCA RATON, Fla, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the intro
Read more →SRTSSensus Healthcare to Present at the H.C. Wainwright 24th Annual Global Investment Conference
BOCA RATON, Fla., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that ma
Read more →SRTSSensus Healthcare Adds Dr. Mohammad K. Khan to Medical Advisory Board
BOCA RATON, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the add
Read more →SRTSSensus Healthcare Launches Upgrade to its SRT-100 Vision System with New State-of-the-Art Ultrasound Capabilities
BOCA RATON, Fla, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces an upgrad
Read more →SRTSSensus Healthcare Second Quarter 2022 Financial Results Feature Revenue Growth of 124% Diluted EPS of $0.21 compares with $(0.02) for the year-ago quarter Affirms expectations for full-year profitability Conference call
Sensus Healthcare Second Quarter 2022 Financial Results Feature Revenue Diluted EPS of $0.21 compares with $(0.02) for the year-ago quarter Affirms expectations for full-year profitability Conference call begins at 4:30 p.m. BOCA RATON, Fla. (August 4, 2022) - Sensus Healt
Read more →SRTS▲ +9.7%on this news
Sensus Healthcare Takes Order for 10 TransDermal Infusion Systems™ Supporting Hair Enhancement Centers Expansion Along with U.SK Under Skin’s Hair-Health Serum
BOCA RATON, Fla., July 27, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces the sale
Read more →SRTS▼ -9%on this newsshared move
Sensus Healthcare to Host Second Quarter 2022 Financial Results and Business Update Conference Call on August 4, 2022
BOCA RATON, Fla., July 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference ca
Read more →SRTSSensus Healthcare to Participate in the H.C. Wainwright Global Investment Conference
BOCA RATON, Fla, May 18, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for oncological and non-oncological conditions, announces that manag
Read more →SRTSSensus Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237% Diluted EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter Affirms expectations for continued growth in the sec
Healthcare First Quarter 2022 Financial Results Feature Revenue Growth of 237% EPS from operations of $0.20 compare with $(0.07) in the year-ago quarter expectations for continued growth in the second quarter and full year profitability call begins at 4:30 p.m. Eastern time to
Read more →SRTSSensus Healthcare to Host First Quarter 2022 Financial Results and Business Update Conference Call on May 5, 2022
BOCA RATON, Fla, April 21, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference cal
Read more →SRTSSensus Healthcare to Present at Two Investment Conferences in March
BOCA RATON, Fla. , March 09, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that m
Read more →SRTSSensus Healthcare Announces Share Repurchase Program BOCA RATON, Fla. (
Sensus Healthcare Announces Share Repurchase BOCA RATON, Fla. (March 9, 2022) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological
Read more →SRTSSensus Healthcare Sells Its Sculptura™ Assets to Empyrean Medical Systems for $15 Million in Cash
BOCA RATON, Fla., March 02, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces it has
Read more →SRTSSensus Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter 4Q21 diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively Affirms expectations for 1Q22 continued growth and ful
Healthcare Reports Record Sales and Earnings for the 2021 Fourth Quarter diluted EPS of $0.32 on revenues of $13.0 million up 433% and 156%, respectively expectations for 1Q22 continued growth and full-year 2022 profitability call begins at 4:30 p.m. Eastern time today RATON,
Read more →SRTSSensus Healthcare Prepares Organization for Long-term Growth with Three Promotions
BOCA RATON, Fla, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces the following promotions, all effective imm
Read more →SRTSSensus Healthcare to Host Fourth Quarter 2021 Financial Results and Business Update Conference Call on February 10, 2022
BOCA RATON, Fla, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call
Read more →SRTS▲ +11.5%on this news
Sensus Healthcare to Present at the H.C. Wainwright BioConnect Virtual Conference
BOCA RATON, Fla. , Jan. 06, 2022 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Jo
Read more →SRTSSensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference Expects profitability for the 2021 fourth quarter and full year Phys
Sensus Healthcare Expects Record 4Q 2021 Sales and Continued Growth in 1Q 2022; Profiles New Product at the 2022 Winter Clinical Dermatology Conference Expects profitability for the 2021 fourth quarter and full year Physician KOL presentation at the Winter Clinical to highli
Read more →SRTS▲ +12.2%on this news
Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System
BOCA RATON, Fla, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the signi
Read more →SRTSSensus Healthcare Reports Third Quarter 2021 Financial Results Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago Affirms expectations for continued growth in 4Q and full-year pro
Sensus Healthcare Reports Third Quarter 2021 Achieves profitability on revenues of $5.5 million, up sharply from $1.6 million a year ago Affirms expectations for continued growth in 4Q and full-year profitability Conference call begins at 4:30 p.m. Eastern time today BOCA
Read more →SRTSSensus Healthcare to Host Third Quarter 2021 Financial Results and Business Update Conference Call on November 4, 2021
BOCA RATON, Fla, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call
Read more →SRTSSensus Healthcare to Participate in Fireside Chat Hosted by Maxim Group and M-Vest
BOCA RATON, Fla, Oct. 15, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that Jose
Read more →SRTSSensus Healthcare Announces Presentations, Demonstrations and Exhibit Booth at the 2021 Fall Clinical Conference in Las Vegas
Premier gathering expected to host more than 1,200 physicians with 500 virtual participants is the first in-person dermatology medical conference in 18 months Multiple tailwinds combine to support Sensus’ expectations for strong sales in 2H 2021 BOCA RATON, Fla., Oct. 07, 2021
Read more →SRTSSensus Healthcare to Participate at H.C. Wainwright 23rd Annual Global Investment Conference
Boca Raton, Fla., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced that J
Read more →SRTSSensus Healthcare Reports Second Quarter 2021 Financial Results Revenues of $5.4 million up 358% year-over-year, up 77% sequentially Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare Reports Second Quarter 2021 Revenues of $5.4 million up 358% year-over-year, Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (August 5, 2021) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly e
Read more →SRTSSensus Healthcare to Host Second Quarter 2021 Financial Results and Business Update Conference Call on August 5, 2021
BOCA RATON, Fla, July 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call
Read more →SRTSSensus Healthcare Announces Participation in A.G.P.’s Virtual MedTech Summer Conference on July 29, 2021
BOCA RATON, Fla. , July 22, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced t
Read more →SRTSSensus Healthcare Reports First Quarter 2021 Financial Results Revenues up 83% year-over-year Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare Reports First Quarter 2021 Financial Revenues up 83% year-over-year Conference call begins at 4:30 p.m. BOCA RATON, Fla. (May 6, 2021) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimall
Read more →SRTSSensus Healthcare to Host First Quarter 2021 Financial Results and Business Update Conference Call on May 6, 2021
BOCA RATON, Fla. , April 29, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference c
Read more →SRTSSensus Healthcare Announces the Sale/Install of its 500th Unit
BOCA RATON, FL, April 13, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced the
Read more →SRTSSensus Healthcare to Participate in Three Investment Conferences During the Month of March
BOCA RATON, Fla, March 08, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced t
Read more →SRTSSensus Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results Achieves fourth quarter net income of $1.0 million on revenues of $5.1 million Conference call begins at 4:30 p.m. Eastern time today BOCA RAT
Healthcare Reports Fourth Quarter and Full Year 2020 Financial Results fourth quarter net income of $1.0 million on revenues of $5.1 million call begins at 4:30 p.m. Eastern time today RATON, Fla. (February 25, 2021) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device c
Read more →SRTSSensus Healthcare Granted U.S. Patent for Three-Dimensional Beam Forming X-Ray Source
BOCA RATON, Fla, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, today announced tha
Read more →SRTSSensus Healthcare to Host Fourth Quarter 2020 Financial Results and Business Update Conference Call on February 25, 2021
BOCA RATON, Fla, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference call
Read more →SRTSSensus Healthcare Engages Ekpac Healthcare Ltd. as New Exclusive Distributor in China for SRT-100™ Systems
BOCA RATON, Fla., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that it
Read more →SRTSSensus Healthcare Announces CMS Sets Rates Higher for SRT Reimbursement
Centers for Medicare & Medicaid Services sets a 66% increase in reimbursement for Radiation Treatment Delivery code 77401, and increases related Evaluation & Management codes Rates to go into effect as of January 1, 2021 BOCA RATON, Fla, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Sensus
Read more →SRTSSensus Healthcare Announces Study Showing Single Low Dose of Superficial Radiation Therapy Prevents Keloid Recurrence Following Surgical Excision
Prospective study published in Journal of the American Academy of Dermatology BOCA RATON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective trea
Read more →SRTSSensus Healthcare Appoints Megan Cornish to its Board of Directors
Gains valuable Capitol Hill, business strategy and marketing experience BOCA RATON, Fla, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treat
Read more →SRTSSensus Healthcare Reports Third Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare Reports Third Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (November 5, 2020) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minima
Read more →SRTSSensus Healthcare to Host Third Quarter 2020 Financial Results and Business Update Conference Call on November 5, 2020
BOCA RATON, Fla. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference c
Read more →SRTSSensus Healthcare Announces Publication of Study Showing Use of Superficial Radiation Therapy Post-Keloidectomy Prevents Keloid Recurrence
Keloid recurrence rate of 10.4% at 12 months for patients treated with SRT following keloidectomy compares with more than 80% with surgical excision alone Retrospective study published in Journal of Clinical and Aesthetic Dermatology BOCA RATON, Fla., Oct. 22, 2020 (GLOBE NEWSW
Read more →SRTSSensus Healthcare Reports Second Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare Reports Second Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (August 6, 2020) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimal
Read more →SRTSSensus Healthcare Acquires Two Mobile Aesthetic Laser Companies in Florida Establishes new line of business, adds recurring revenue stream while more than doubling dermatology customer base across the state Expected to a
Acquires Two Mobile Aesthetic Laser Companies in Florida Fla. (August 4, 2020) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological
Read more →SRTSSensus Healthcare to Host Second Quarter 2020 Financial Results and Business Update Conference Call on August 6, 2020
BOCA RATON, Fla. , July 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference ca
Read more →SRTSSensus Healthcare Names Hoi-Bun “Benson” Suen Vice President of International Sales, Ships SRT-100™ to China
BOCA RATON, Fla. , July 28, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the app
Read more →SRTSSensus Healthcare to Present at COVID-19 Webinar Hosted by Maxim Group on July 16th
BOCA RATON, Fla., July 13, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, Sensus’ chief exec
Read more →SRTSSensus Healthcare’s CEO to Participate in Dermatology Practice Panel Discussion as Part of the Fall Clinical Virtual Grand Rounds Weekly Series
BOCA RATON, Fla. , June 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Joe Sardano, the company’s chief exe
Read more →SRTSSensus Healthcare Announces CME Presentation by Dr. Jeffrey S. Fromowitz Today at the Fall Clinical Virtual Grand Rounds Series
BOCA RATON, Fla, June 24, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that Jeffrey S. Fromowitz, M.D. will discus
Read more →SRTSSensus Healthcare and David Goldberg, M.D., J.D. to Host a Virtual Program on Dermatology Medical and Legal Issues in the Era of COVID-19
June 18 Event is the Third in a Series of Topical Discussions BOCA RATON, Fla., June 03, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological c
Read more →SRTSSensus Healthcare Reports First Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Sensus Healthcare Reports First Quarter 2020 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (May 7, 2020) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-i
Read more →SRTSSensus Healthcare to Host First Quarter 2020 Financial Results and Business Update Conference Call on May 7, 2020
BOCA RATON, Fla. , April 30, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference
Read more →SRTSSensus Healthcare Announces Publication of Research on Long-term Efficacy and Safety of Superficial Radiation Therapy in Journal of Drugs in Dermatology
Retrospective registry study showed a 98.9% non-recurrence rate after 85 months in subjects with non-melanoma skin cancer treated with SRT BOCA RATON, Fla. , March 03, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highl
Read more →SRTSSensus Healthcare Reports Fourth Quarter and Full Year 2019 Financial Results Fourth quarter net income up 10-fold to $1.0 million, diluted EPS of $0.06 Conference call begins at 4:30 p.m. Eastern time today BOCA RATON,
Sensus Healthcare Reports Fourth Quarter and Full Year 2019 Financial Results Fourth quarter net income up 10-fold to $1.0 million, diluted EPS of $0.06 Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (February 13, 2020) - Sensus Healthcare, Inc. (N
Read more →SRTSSensus Healthcare to Host Fourth Quarter 2019 Financial Results and Business Update Conference Call on February 13, 2020
BOCA RATON, Fla. , Feb. 06, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference ca
Read more →SRTSSensus Healthcare Announces Sculptura™ Shipment to California-based Medical Center Third Sculptura system sold worldwide
BOCA RATON, Fla, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, is pleased to annou
Read more →SRTSSensus Healthcare Announces Management Promotions
New corporate structure positions company for 2020 financial goals BOCA RATON, Fla., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatment
Read more →SRTSSensus Healthcare to Present at the Piper Jaffray 31st Annual Healthcare Conference
BOCA RATON, Fla., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announced today th
Read more →SRTSSensus Healthcare Reports Third Quarter 2019 Financial Results
Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncol
Read more →SRTSSensus Healthcare Reports Third Quarter
Sensus Healthcare Reports Third Quarter 2019 Financial Results Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (November 6, 2019) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minima
Read more →SRTSSensus Healthcare to Host Third Quarter 2019 Financial Results and Business Update Conference Call on November 6, 2019
BOCA RATON, Fla., Nov. 01, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference cal
Read more →SRTSSensus Healthcare Reports Second Quarter
Sensus Healthcare Reports Second Quarter 2019 Financial Results BOCA RATON, Fla. (August 8, 2019) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for both oncol
Read more →SRTSSensus Healthcare Reports Second Quarter 2019 Financial Results
· Resumes double-digit revenue growth, up 23% over the prior year quarter · Affirms expectations for full-year double-digit revenue growth · Conference call begins at 4:30 p.m. East ern time today BOCA RATON, Fla., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (N
Read more →SRTSSensus Healthcare to Host Second Quarter 2019 Financial Results and Business Update Conference Call on August 8, 2019
BOCA RATON, Fla., July 30, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announces that management will hold a conference cal
Read more →SRTSSensus Healthcare to Present at the Raymond James Inaugural Life Sciences and MedTech Conference
BOCA RATON, Fla., June 10, 2019 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, announced today that Joe Sardano, CEO of the Company
Read more →SRTSSensus Healthcare Reports First Quarter 2019 Financial Results Premier, Inc. adds SRT to its group purchasing contracts Ships second Sculptura system to Rabin Medical Center in Israel Reaffirms expectations for double-di
Sensus Healthcare Reports First Quarter 2019 Financial Results BOCA RATON, Fla. (May 9, 2019) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive treatments for both oncological and non-oncological conditions, anno
Read more →SRTSSensus Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth Shipped 27 systems during the quarter including 15 SRT-100 Vision systems Conference call begins at 4:30 p.m. Ea
Healthcare Fourth Quarter Financial Results Feature Record Revenue and Continued Double-digit Growth 27 systems during the quarter including 15 SRT-100 Vision systems call begins at 4:30 p.m. Eastern time today RATON, Fla. (February 14, 2019) - Sensus Healthcare, Inc. (Nasdaq:
Read more →SRTSSensus Healthcare Third Quarter Financial Results Feature Revenue Growth of 32% Shipped 18 systems during the quarter including 15 SRT-100 Vision systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON,
Healthcare Third Quarter Financial Results Feature Revenue Growth of 32% 18 systems during the quarter including 15 SRT-100 Vision systems call begins at 4:30 p.m. Eastern time today RATON, Fla. (November 1, 2018) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device comp
Read more →SRTSSensus Healthcare, Inc. Announces Underwriters' Exercise of Option
Healthcare, Inc. Announces Underwriters' Exercise of Option RATON, Fla., September 21, 2018 - Sensus Healthcare, Inc. [Nasdaq:SRTS] announced today that it has issued an additional 330,882 shares of its common stock pursuant to the exercise in full of the underwriters' option r
Read more →SRTSSensus Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth Ships 21 systems including 12 SRT-100 Vision systems Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (
Healthcare Second Quarter Financial Results Feature Continued Strong Revenue Growth 21 systems including 12 SRT-100 Vision systems call begins at 4:30 p.m. Eastern time today RATON, Fla. (August 2, 2018) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specia
Read more →SRTSSensus Healthcare Reports First Quarter Financial Results Featuring 37% Revenue Growth Ships 21 systems with SRT-100 Vision systems sales continuing to rise Conference call begins at 4:30 p.m. Eastern time today BOCA RAT
Healthcare Reports First Quarter Financial Results Featuring 37% Revenue Growth 21 systems with SRT-100 Vision systems sales continuing to rise call begins at 4:30 p.m. Eastern time today RATON, Fla. (May 3, 2018) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device comp
Read more →SRTSSensus Healthcare Reports Record Revenue for 2017 Fourth Quarter and Full Year Ninth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fl
Sensus Healthcare Reports Record Revenue for 2017 Fourth Quarter and Full Year Ninth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 p.m. Eastern time today BOCA RATON, Fla. (February 1, 2018) - Sensus Healthcare, Inc. (Nasd
Read more →SRTSSensus Healthcare Reports Third Quarter Financial Results Featuring Revenue up 44% Marks eighth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 p.m. Eastern time today BOC
Healthcare Reports Third Quarter Financial Results Featuring Revenue up 44% eighth consecutive quarter of double-digit year-over-year revenue growth call begins at 4:30 p.m. Eastern time today RATON, Fla. (November 2, 2017) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical d
Read more →SRTSSensus Healthcare to Present at Upcoming Investor Conferences
BOCA RATON, Fla., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), today announced that Joe Sardano, Pre
Read more →SRTSSensus Healthcare to Present at the 6th Annual Liolios Gateway Conference on September 6, 2017
BOCA RATON, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), has been invited to present at the 201
Read more →SRTSSensus Healthcare Reports Record Second Quarter Financial Results Revenue growth of 39% marks seventh consecutive quarter of double-digit year-over-year gains Conference call begins at 4:30 Eastern time today BOCA RATON,
Healthcare Reports Record Second Quarter Financial Results growth of 39% marks seventh consecutive quarter of double-digit year-over-year gains call begins at 4:30 Eastern time today RATON, Fla. (August 3, 2017) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device compan
Read more →SRTSSensus to Present at the 2017 Marcum MicroCap Conference
BOCA RATON, Fla., June 05, 2017 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq:SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids, with superficial radiation therapy (SRT), today announced Joe Sardano, the Comp
Read more →SRTSSensus Healthcare First Quarter Financial
Sensus Healthcare First Quarter Financial Results Feature Revenues up 43% Sixth consecutive quarter of double-digit year-over-year revenue growth Conference call begins at 4:30 BOCA RATON, Fla. (May 4, 2017) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company
Read more →SRTSSensus Healthcare Reports Fourth Quarter and Full Year 2016 Results - Record Quarterly Revenues of $4.9 million in Fourth Quarter - Full Year 2016 revenues increased 44% year-over-year to $14.8 million - Worldwide instal
Sensus Healthcare Reports Fourth Quarter and Full Year 2016 Results Revenues of $4.9 million in Fourth Quarter revenues increased 44% year-over-year to $14.8 million - Worldwide installed base increased to 271 units BOCA RATON, Fla., Feb. 2, 2017 /PRNewswire/ - Sensus Heal
Read more →SRTSSensus Healthcare Reports Third Quarter 2016 Results - Q3 revenues increased 58% year-over-year to $3.33 million - Worldwide installed base increased to 256 units
Sensus Healthcare Reports Third Quarter - Q3 revenues increased 58% year-over-year to $3.33 million - Worldwide installed base increased to 256 units BOCA RATON, Fla., Nov. 3, 2016 /PRNewswire/ - Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in
Read more →SRTSSENSUS HEALTHCARE REPORTS SECOND QUARTER 2016 RESULTS - Q2 revenues increased 49% year-over-year to $3.6 million - Worldwide installed base increased to 247 units -Successfully completed IPO on June 2 nd ; cash of $15.8
REPORTS SECOND QUARTER 2016 RESULTS increased 49% year-over-year to $3.6 million installed base increased to 247 units completed IPO on June 2nd; cash of $15.8 million, with no debt, at June 30, 2016 Fla. - August 4, 2016 - Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical de
Read more →SRTSSensus Healthcare, Inc. Announces Separation of Units Sold in
Sensus Healthcare, Inc. Announces Separation of Units Sold in IPO BOCA RATON, Fla. - July 21, 2016 - Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with s
Read more →SRTSSensus Healthcare, Inc. Appoints Dr. Darrell Rigel to its Board of Directors --Past President of both the American Academy of Dermatology and American Society for Dermatologic Surgery --Recipient of American Academy of D
Sensus Healthcare, Inc. Appoints Dr. Darrell Rigel to its Board of Directors --Past President of both the American Academy of Dermatology and American Society for Dermatologic Surgery --Recipient of American Academy of Dermatology's Gold Medal in Recognition of a Lifetime o
Read more →SRTSSensus Healthcare, Inc. Announces Completion of Initial Public Offering, including Underwriters' Exercise of Over-Allotment Option in Full
Healthcare, Inc. Announces Completion of Initial Public Offering, including Underwriters' Exercise of Over-Allotment Option BOCA RATON, Fla. - June 8, 2016 - Sensus Healthcare, Inc. (NASDAQ: SRTSU), a medical device company specializing in the treatment of non-melanoma skin can
Read more →SRTSSensus Healthcare (Nasdaq: SRTSU) to Ring The Nasdaq Stock Market Opening Bell
ADVISORY, June 08, 2016 (GLOBE NEWSWIRE) -- Sensus Healthcare (Nasdaq:SRTSU), a medical device company specializing in the treatment of non-melanoma skin cancers and other skin conditions, such as keloids, with superficial radiation therapy, will visit the Nasdaq MarketSite in T
Read more →SRTSSensus Healthcare Receives FDA 510k Clearance for Next Generation Image Guided Superficial Radiotherapy SRT-100 Vision(TM)
SAN ANTONIO, Oct. 19, 2015 (GLOBE NEWSWIRE) -- Sensus Healthcare, the market leader in superficial radiation therapy treatment of skin cancer and keloids, announces FDA clearance for the next generation SRT-100 Vision system at the American Society for Radiation Oncology (ASTRO)
Read more →SRTSSensus Healthcare Teams Up with Jeffrey Klein MD and Dermatology Associates of Orange County to Offer Non-Invasive Procedure for Non-Melanoma Skin Cancers
BOCA RATON, Fla., May 19, 2015 (GLOBE NEWSWIRE) -- Sensus Healthcare, a manufacturer and marketer of medical devices that incorporate superficial radiation therapy (SRT) for noninvasive treatment of non-melanoma skin cancers and keloids, proudly announces a new physician-user to
Read more →Competitive Position
How SRTS ranks across every disease it competes inCompetitive Position is a premium feature
See how SRTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial